Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-12-30
2009-10-13
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388150
Reexamination Certificate
active
07601353
ABSTRACT:
The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.
REFERENCES:
patent: 5494791 (1996-02-01), Cohen
patent: 5861276 (1999-01-01), Kwak et al.
patent: 5972890 (1999-10-01), Lees et al.
patent: 6225070 (2001-05-01), Witztum et al.
patent: 2007/0098725 (2007-05-01), Nilsson et al.
patent: 0433088 (1997-06-01), None
patent: WO9832845 (1998-07-01), None
patent: WO9842751 (1998-10-01), None
patent: WO 99/08109 (1999-02-01), None
patent: WO9908109 (1999-02-01), None
patent: WO 99/18986 (1999-04-01), None
patent: WO9918986 (1999-04-01), None
patent: WO0132070 (2001-05-01), None
patent: WO0164008 (2001-09-01), None
patent: WO02080954 (2002-10-01), None
Tinahones et al., Journal of Lipid Research, 2005, 46:452-457.
Ameli et al., 1996, Arterioscler. Thromb. Vasc. Biol., 16:1074-9.
Fredrikson et al., 2003, Arterioscler. Thromb. Vasc. Biol., 23(5):879-84.
Schiopu et al., 2006, Clin. Immunol., 119:S147-8.
Strom et al., 2007, Atherosclerosis, 190:298-305.
Borrebaeck and Carlsson (2001) Curr. Opin. Pharmacol., 1:404-8.
Bruce et al. (1999) Int. J. Biochem. Cell Biol., 1409-20.
Caligiuri et al. (2002) J. Clin. Invest., 109:745-753.
Dimayuga et al. (2002) Arterioscl. Thromb. Vasc. Biol., 22:644-9.
Freigang et al. Arterioscl. Thromb. Vasc. Biol. (1998) 1973-82.
George et al. (1998) Atherosclerosis, 138:147-52.
Griffiths et al. (1994) EMBO J., 13:3245-3260.
Hammer et al. (1995) Aterioscl. Thromb. Vasc. Biol., 704-13.
Hoogenboom et al. (1992) J. Mol. Biol., 227:381-8.
Jovinge et al. (1997) Aterioscl. Thromb. Vasc. Biol., 17:2225-31.
Li et al. (2000) Biochemistry, 39 6296-6309.
McCafferty et al. (1990) Nature, 348:552-4.
Merck Manual of Diagnosis and Therapy (1999; 17th ed.) pp. 1656-1657.
Milstein and Kohler (1975) Nature, 256:495-7.
Neuberger et al. (1985) Nature, 314:268-70.
Palinski et al. (1989) Proc. Natl. Acad. Sci. USA, 86:1372-6.
Palinski et al. (1995) Proc. Natl. Acad. Sci. USA, 92:821-5.
Reff et al. (2001) Crit. Rev. Oncol/Hematol. 40:25-35.
Regnstrom et al. Atherosclerosis, 82:43-51.
Soderlind et al. (2000) Nature BioTechnol., 18:851-6.
Soderlind et al. (2001) Comb. Chem & High Throughput Screen, 4:409-16.
Steinberg et al. (1989) New England J. Med., 320:915-924.
Tinahones et al. (2005) J. Lipid Res. 46:452-7.
Valentinova et al. (1994) Biol. Chem., 651-8.
Zhou et al. (1998) J. Clin. Invest.,101:1717-25.
Reff et al., “A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications” Oncology Hematology, (2001) pp. 25-35.
The Merck Manual of Diagnosis and Therapy. 17thEdition, published by Merk Research Labratories, 1999, pp. 1654-1659.
Tinahones et al., “Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population” Journal of Lipid Research, vol. 46, 2005, pp. 452-457.
Li et al., “Three-Dimensional Structures of the Free and Antigen-Bound Fab from the Monoclonal Antilysozyme Antibody HyHEL-63” Biochemistry 2000, pp. 6296-6309.
Bengtsson Jenny
Carlsson Roland
Nilsson Jan
Strandberg Leif
Forskarpatent I SYD AB
Gauthier & Connors LLP
Ouspenski Ilia
LandOfFree
Peptide-based passive immunization therapy for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide-based passive immunization therapy for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide-based passive immunization therapy for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4072465